Crispr Therapeutics (NASDAQ:CRSP) and Incyte (INCY) Head to Head Analysis

Crispr Therapeutics (NASDAQ: CRSP) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Crispr Therapeutics and Incyte, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Crispr Therapeutics 0 3 3 0 2.50
Incyte 0 5 18 0 2.78

Crispr Therapeutics currently has a consensus price target of $22.81, indicating a potential downside of 20.01%. Incyte has a consensus price target of $142.86, indicating a potential upside of 51.86%. Given Incyte’s stronger consensus rating and higher probable upside, analysts clearly believe Incyte is more favorable than Crispr Therapeutics.

Insider and Institutional Ownership

21.9% of Crispr Therapeutics shares are owned by institutional investors. Comparatively, 90.8% of Incyte shares are owned by institutional investors. 40.0% of Crispr Therapeutics shares are owned by company insiders. Comparatively, 17.7% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Crispr Therapeutics and Incyte’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Crispr Therapeutics -466.58% -38.42% -25.26%
Incyte -10.90% -12.91% -7.41%

Valuation and Earnings

This table compares Crispr Therapeutics and Incyte’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Crispr Therapeutics $5.16 million 253.64 -$23.17 million ($0.32) -89.13
Incyte $1.11 billion 17.95 $104.22 million ($0.80) -117.59

Incyte has higher revenue and earnings than Crispr Therapeutics. Incyte is trading at a lower price-to-earnings ratio than Crispr Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Incyte beats Crispr Therapeutics on 9 of the 13 factors compared between the two stocks.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.